Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Materials
DSM Boosts Role In Biomedical Materials
by Michael McCoy
May 7, 2012
| A version of this story appeared in
Volume 90, Issue 19
DSM plans to acquire Kensey Nash, a U.S.-based biomedical materials company, for about $360 million. The deal, approved by Kensey Nash’s board, represents a 33% premium over Kensey Nash’s recent share price. Based in Exton, Pa., Kensey Nash makes medical device parts using collagen and synthetic polymer technology. It expects to have sales of $90 million for the fiscal year ending June 30. DSM CEO Feike Sijbesma says his firm is well positioned to expand in biomedical materials because of its presence in both the life sciences and materials sectors.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter